Search research articles
Contact Us
Filters
Showing results (81-90 of 218) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2024
DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group
Vivek M Shastri, Lata Chauhan, Mohammed Gbadamosi, et al.
Biorxiv : the Preprint Server for Biology
|
January 18, 2024
KMT2A oncoproteins induce epigenetic resistance to targeted therapies
Derek H Janssens, Melodie Duran, Dominik J Otto, et al.
Blood
|
October 5, 2010
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations
John A Pulikkan, Philomina S Peramangalam, Viola Dengler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 25, 2019
A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study
Stella M Davies, Robert Iannone, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Adam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Pediatric Blood & Cancer
|
March 2, 2012
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group
Matthew A Kutny, Barry K Moser, Kristina Laumann, et al.
Blood
|
March 2, 2012
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
Jessica A Pollard, Todd A Alonzo, Michael Loken, et al.
Blood
|
June 1, 2012
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R Loken, Todd A Alonzo, Laura Pardo, et al.
American Journal of Hematology
|
September 4, 2025
Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF-TD to Venetoclax/Azacitidine
Pietro Merli, Riccardo Masetti, Martina Pigazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2017
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631
Matthew A Kutny, Todd A Alonzo, Robert B Gerbing, et al.
Page
of 22
Search research articles
Search
Showing results (81-90 of 218) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2024
DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group
Vivek M Shastri, Lata Chauhan, Mohammed Gbadamosi, et al.
Biorxiv : the Preprint Server for Biology
|
January 18, 2024
KMT2A oncoproteins induce epigenetic resistance to targeted therapies
Derek H Janssens, Melodie Duran, Dominik J Otto, et al.
Blood
|
October 5, 2010
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations
John A Pulikkan, Philomina S Peramangalam, Viola Dengler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 25, 2019
A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study
Stella M Davies, Robert Iannone, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Adam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Pediatric Blood & Cancer
|
March 2, 2012
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group
Matthew A Kutny, Barry K Moser, Kristina Laumann, et al.
Blood
|
March 2, 2012
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
Jessica A Pollard, Todd A Alonzo, Michael Loken, et al.
Blood
|
June 1, 2012
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R Loken, Todd A Alonzo, Laura Pardo, et al.
American Journal of Hematology
|
September 4, 2025
Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF-TD to Venetoclax/Azacitidine
Pietro Merli, Riccardo Masetti, Martina Pigazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2017
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631
Matthew A Kutny, Todd A Alonzo, Robert B Gerbing, et al.
Page
of 22